Immuneering Corporation
IMRX•NASDAQ•Healthcare•Biotechnology

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOBenjamin Zeskind
Founded2008
IPO DateJuly 30, 2021
Employees66
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock
Share ClassClass A Shares

Contact Information

Websiteimmuneering.com
Phone617 500 8080
Address
245 Main Street, Second Floor Cambridge, Massachusetts 02142 United States

Corporate Identifiers

CIK0001790340
CUSIP45254E107
ISINUS45254E1073
SIC2834

Leadership Team & Key Executives

Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Co-Founder, President, Chief Executive Officer and Director
Robert J. Carpenter M.B.A., M.S.
Co-Founder and Chair Emeritus
Dr. Brett M. Hall Ph.D.
Chief Scientific Officer
Michael D. Bookman J.D.
Chief Legal Officer and Secretary
Mallory Morales CPA
Principal Financial and Accounting Officer, Chief Accounting Officer and Treasurer
Paula George CPA
Director of Accounting and Operations and Assistant Corporate Controller
Leah R. Neufeld
Chief People Officer
Dr. Peter King Ph.D.
Head of Discovery and Vice President
Dr. Praveen Nair Ph.D.
Head of Translational Pharmacology and Vice President
Harold E. Brakewood
Chief Business Officer